Journey Medical Corporation Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
Provided By GlobeNewswire
Last update: May 14, 2025
Revenue for the First Quarter Ended March 31, 2025 was $13.1 million
Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules) Commercial Launch Off to a Strong Start, Initial Prescriptions Filled in Late March 2025
Read more at globenewswire.com6.35
+0.04 (+0.63%)
NASDAQ:FBIO (6/18/2025, 8:00:01 PM)
1.81
-0.02 (-1.09%)
Find more stocks in the Stock Screener
